Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ARMO BioSciences
Biotech
Lilly cans pancreatic cancer program for Armo buyout drug
Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.
Amirah Al Idrus
Oct 23, 2019 9:20am
Lilly's Armo buyout drug a bust in pancreatic cancer
Oct 16, 2019 7:28am
Cel-Sci CEO paints 'promising future' in letter to shareholders
Aug 22, 2018 8:09am
Lilly boosts immuno-oncology pipeline with $1.6B Armo buy
May 10, 2018 10:38am
Armo taps Celgene, GV for $67M to fuel late-phase I-O R&D
Aug 30, 2017 9:09am
